Examining the neuromodulatory effects of cannabidiol in healthy adults

Examining the neuromodulatory effects of cannabidiol in healthy adults: A randomised, double-blind, placebo-controlled, cross-over trial

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12626000609358

Acronym

CBD-EEG

Enrollment

Registered

2026-05-18

Start date

2026-06-01

Completion date

2026-11-30

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This project will be the first to comprehensively test the hypothesis that oral administration of cannabidiol (CBD) oil modulates brain excitation-inhibition (E-I) using a range of electrophysiological measures (aperiodic activity, gamma band oscillatory activity, mismatch negativity) using electroencephalography (EEG) in neurotypical adults. To that end, we will conduct a randomised, double-blind, placebo-controlled, crossover trial to examine the effect of acute dose 600mg CBD oil on EEG-derived measures of brain E-I.

Interventions

- 600mg cannabidiol (CBD) suspended in 6ml of medium-chain triglyceride (MCT) oil plus flavouring. - Single dose, administered oralorally (oil held under tongue for 1 minute). - Adherence will be monitored by trial staff observing participants hold the oil in their mouth for 1 minute (timed by trial staff) before swallowing. - 2-week washout between active and placebo interventions.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Educational / counselling / training

Masking

Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

• Age 18-40 years • Male or female • Fluent in written and spoken English • Normal or corrected-to-normal vision • Normal hearing • No intellectual disability • Willing to undergo urine and blood sample collection

Exclusion criteria

• Known hypersensitivity to CBD, THC, cannabis or excipients used in product manufacture (MCT oil) • Medicinal cannabis (on prescription) or illicit cannabis use (including unregulated CBD products) in the past 6 months • Pregnant, breastfeeding or planning to become pregnant during the trial • Current psychiatric, developmental, substance use, genetic, and neurological conditions • Intellectual disability • Currently taking psychoactive medications (e.g., benzodiazepines)

Outcome results